Proto Oncogene Drug Market By Product ( Axitinib, Ponatinib, Imatinib, Sunitinib, Pazopanib, Dabrafenib, Vandetanib, Vemurafenib, Cabozantinib ), By Application ( Clinics, Hospitals, Research Labs & Others ), Industry Trends, Estimation & Forecast, 2017 - 2025

Proto Oncogene Drug Market is expected to grow with a CAGR of XX% during the forecast period of 2018 to 2025.

Market Overview:

A proto-oncogene is a gene that has a tendency to become an oncogene as a result of mutations. Proto-oncogenes direct the proteins which support to regulate cell growth and differentiation. When the proto-oncogene attains an activating mutation, it becomes a tumor-generating agent in the form of oncogene. There are various types of proto-oncogenes such as RAS, WNT, MYC and many others. The tumor caused by this mutation, turns out in the form of Cancer. In the current scenario, cancer is considered to be a complex genetic disease. This is the reason, conventional anti-cancer, oncogene inhibition therapies are preferred in order to kill the tumor cells and restrain the sudden mutations. With the continuous advancement in technology, there are nearly 20 types of commercialized proto-oncogene inhibitor drugs available in the market. This is because Cancer, is rapidly spreading as a major disease, generating serious concerns all around the world. As per American Cancer Society, One out of every two men and one out of every three women have a tendency to generate cancer within them in their lifespan. Proto-oncogene drug market is exhibiting a rapid growth at different levels as, pharmaceutical companies are strongly emphasizing on the provision of most efficient cancer drugs and in return, generating significant revenues through sales. The presence of a substantial cancer patient base and continuous development in drug therapy are the propelling agents for the growth of the very market. In addition to this, continuous initiatives taken by governments to increase awareness regarding cancer and its cure, coupled with the increasing R&D funds for the development of new formulations in order to decrease the side effects and increase the drug effectiveness will emerge out as the highly contributing factors for the growth of proto-oncogene drug market in the near future. However, the high cost of these drugs and lack of awareness among patients might act as a restraining factor for the growth of the very market. The report provides detailed qualitative and quantitative analysis of the Global Proto Oncogene Drug Market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely product and application in each of the major regions.

Proto Oncogene Drug Market Segmentation

By Product • Axitinib (Inlyta) • Ponatinib (Iclusig) • Imatinib (Gleevec) • Sunitinib (Sutent) • Pazopanib (Votrient) • Dabrafenib (Tafinlar) • Vandetanib (Caprelsa) • Vemurafenib (Zelboraf) • Cabozantinib (Cabometyx & Cometriq) • Sorafenib (Nexavar) By Application • Clinics • Hospitals • Research Labs & Others By Geography • North America o U.S. o Canada o Mexico • Europe o U.K. o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION 1.1. RESEARCH METHODOLOGY 1.1.1. ERC desk research 1.1.2. ERC data synthesis 1.1.3. Data validation and market feedback 1.1.4. ERC data sources CHAPTER 2. PROTO ONCOGENE MARKET OVERVIEW 2.1. PROTO ONCOGENE DRUG MARKET INTRODUCTION 2.2. GLOBAL PROTO ONCOGENE DRUG MARKET PRODUCTION AND GROWTH RATE, 2017-2025 2.2.1. Global Proto Oncogene Drug Production (Volume) and Growth Rate (%), (2017-2025) 2.3. GLOBAL PROTO ONCOGENE MARKET CAPACITY AND GROWTH RATE, 2017-2025 2.3.1. Global Proto Oncogene Drug Capacity (Volume) and Growth Rate (%), (2017-2025) 2.4. GLOBAL PROTO ONCOGENE DRUG MARKET REVENUE AND GROWTH RATE, 2017-2025 2.4.1. Global Proto Oncogene Drug Market Revenue (Million USD) and Growth Rate (%), (2017-2025) 2.5. GLOBAL PROTO ONCOGENE DRUG MARKET CONSUMPTION AND GROWTH RATE, 2017-2025 2.5.1. Global Proto Oncogene Drug Consumption (Volume) and Growth Rate (%), (2017-2025) 2.6. GLOBAL PROTO ONCOGENE DRUG MARKET PRICE TREND, 2017-2025 2.6.1. Global Proto Oncogene Drug Market Price Trend (USD/ UNIT) and Growth Rate (%), (2017-2025) CHAPTER 3. GLOBAL PROTO ONCOGENE DRUG MARKET BY PRODUCT, 2017-2025 3.1. AXITINIB (INLYTA) 3.2. PONATINIB (ICLUSIG) 3.3. IMATINIB (GLEEVEC) 3.4. SUNITINIB (SUTENT) 3.5. PAZOPANIB (VOTRIENT) 3.6. DABRAFENIB (TAFINLAR) 3.7. VANDETANIB (CAPRELSA) 3.8. VEMURAFENIB (ZELBORAF) 3.9. (CABOMETYX & COMETRIQ) 3.10. SORAFENIB (NEXAVAR) 3.11. GLOBAL PROTO ONCOGENE DRUG MARKET REVENUE BY PRODUCT, 2017-2025 3.11.1. Global Proto Oncogene Market Revenue (Million USD) and Share (%) By Product, 2017-2025 3.11.2. Axitinib (Inlyta) Market Revenue and Growth Rate, 2017-2025 3.11.3. Ponatinib (Iclusig) Market Revenue and Growth Rate, 2017-2025 3.11.4. Imatinib (Gleevec) Market Revenue and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for other product segments. 3.12. GLOBAL PROTO ONCOGENE DRUG MARKET PRODUCTION BY PRODUCT, 2017-2025 3.12.1. Global Proto Oncogene Drug Market Production (Units) and Share (%) By Product, 2017-2025 3.12.2. Axitinib (Inlyta) Market Production and Growth Rate, 2017-2025 3.12.3. Ponatinib (Iclusig) Market Production and Growth Rate, 2017-2025 3.12.4. Imatinib (Gleevec) Market Production and Growth Rate, 2017-2025 Note: Similar information coverage has been provided for other product segments. CHAPTER 4. GLOBAL PROTO ONCOGENE DRUG MARKET BY APPLICATION, 2017-2025 4.1. CLINICS 4.2. HOSPITALS 4.3. OTHERS 4.4. GLOBAL PROTO ONCOGENE DRUG MARKET REVENUE BY APPLICATION, 2017-2025 4.4.1. Global Proto Oncogene Drug Market Revenue (Million USD) and Share (%) By Application, 2017-2025 4.4.2. Clinics Market Revenue and Growth Rate, 2017-2025 4.4.3. Hospitals Market Revenue and Growth Rate, 2017-2025 4.4.4. Others Market Revenue and Growth Rate, 2017-2025 4.5. GLOBAL PROTO ONCOGENE DRUG MARKET CONSUMPTION BY APPLICATION, 2017-2025 4.5.1. Global Proto Oncogene Drug Market Consumption (Units) and share (%) By Application, 2017-2025 4.5.2. Clinics Market Consumption and Growth Rate, 2017-2025 4.5.3. Hospitals Market Consumption and Growth Rate, 2017-2025 4.5.4. Others Market Consumption and Growth Rate, 2017-2025 CHAPTER 5. GLOBAL PROTO ONCOGENE DRUG MARKET BY REGION, 2017-2025 5.1. NORTH AMERICA 5.1.1. U.S. 5.1.2. Canada 5.1.3. Mexico 5.2. EUROPE 5.2.1. U.K. 5.2.2. France 5.2.3. Germany 5.2.4. Italy 5.2.5. Spain 5.2.6. Rest of Europe 5.3. ASIA PACIFIC 5.3.1. China 5.3.2. Japan 5.3.3. India 5.3.4. Korea 5.3.5. Rest of APAC 5.4. SOUTH AMERICA 5.4.1. Brazil 5.4.2. Rest of South America 5.5. REST OF THE WORLD 5.5.1. Middle East 5.5.2. Africa 5.6. GLOBAL PROTO ONCOGENE DRUG MARKET REVENUE BY REGION, 2017-2025 5.6.1. Global Proto Oncogene Drug Market Revenue (Million USD) and Share (%) By Region, 2017-2025 5.6.2. North America Market Revenue and Growth Rate, 2017-2025 5.6.3. Europe Market Revenue and Growth Rate, 2017-2025 5.6.4. Asia Pacific Market Revenue and Growth Rate, 2017-2025 5.6.5. South America Market Revenue and Growth Rate, 2017-2025 5.6.6. Rest of the World Market Revenue and Growth Rate, 2017-2025 CHAPTER 6. GLOBAL PROTO ONCOGENE DRUG MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025 6.1. GLOBAL PROTO ONCOGENE DRUG MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025 6.1.1. Global Proto Oncogene Drug Market Production (Units) and Share (%) By Region, 2017-2025 6.1.2. Global Proto Oncogene Drug Market Consumption (Units) and Share (%) By Region, 2017-2025 6.1.3. North America Market Production and Consumption, 2017-2025 6.1.4. Europe Market Production and Consumption, 2017-2025 6.1.5. Asia Pacific Market Production and Consumption, 2017-2025 6.1.6. South America Market Production and Consumption, 2017-2025 6.1.7. Rest of the World Market Production and Consumption, 2017-2025 CHAPTER 7. MARKET DETERMINANTS 7.1. MARKET DRIVERS 7.2. MARKET RESTRAINTS 7.3. MARKET OPPORTUNITIES 7.4. MARKET DETERMINANTS RADAR CHART CHAPTER 8. GLOBAL PROTO ONCOGENE DRUG MARKET COMPETITION BY MANUFACTURERS 8.1. GLOBAL PROTO ONCOGENE DRUG PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025) 8.1.1. Global Proto Oncogene Production (UNITS) and Share (%) by Manufacturers (2017-2025) 8.2. GLOBAL PROTO ONCOGENE DRUG REVENUE AND SHARE BY MANUFACTURERS (2017-2025) 8.2.1. Global Proto Oncogene Revenue (Million USD) and Share (%) by Manufacturers (2017-2025) 8.3. PROTO ONCOGENE DRUG MARKET COMPETITIVE SITUATION AND TRENDS 8.3.1. Proto Oncogene Drug Market Share (%) of Top 3 Manufacturers 8.3.2. Proto Oncogene Drug Market Share (%) of Top 5 Manufacturers CHAPTER 9. GLOBAL PROTO ONCOGENE DRUG MANUFACTURERS ANALYSIS 9.1. ASTRAZENECA 9.1.1. Business Overview 9.1.2. Company Basic Information 9.1.3. Proto Oncogene Drug Product Details 9.1.4. AstraZeneca Proto Oncogene Production, Revenue and Gross Margin 9.2. ARIAD PHARMACEUTICALS 9.2.1. Business Overview 9.2.2. Company Basic Information 9.2.3. Proto Oncogene Drug Product Details 9.2.4. ARIAD Pharmaceuticals Proto Oncogene Production, Revenue and Gross Margin 9.3. BAYER HEALTHCARE 9.3.1. Business Overview 9.3.2. Company Basic Information 9.3.3. Proto Oncogene Drug Product Details 9.3.4. Bayer Healthcare Proto Oncogene Production, Revenue and Gross Margin 9.4. BRISTOL-MYERS SQUIBB 9.4.1. Business Overview 9.4.2. Company Basic Information 9.4.3. Proto Oncogene Drug Product Details 9.4.4. Bristol-Myers Squibb Proto Oncogene Production, Revenue and Gross Margin 9.5. DEXA MEDICA 9.5.1. Business Overview 9.5.2. Company Basic Information 9.5.3. Proto Oncogene Drug Product Details 9.5.4. Dexa Medica Proto Oncogene Production, Revenue and Gross Margin 9.6. CHEMGENEX PHARMACEUTICALS 9.6.1. Business Overview 9.6.2. Company Basic Information 9.6.3. Proto Oncogene Drug Product Details 9.6.4. ChemGenex Pharmaceuticals Proto Oncogene Production, Revenue and Gross Margin 9.7. EISAI PHARMACEUTICALS 9.7.1. Business Overview 9.7.2. Company Basic Information 9.7.3. Proto Oncogene Drug Product Details 9.7.4. Eisai Pharmaceuticals Proto Oncogene Production, Revenue and Gross Margin 9.8. GLAXOSMITHKLINE 9.8.1. Business Overview 9.8.2. Company Basic Information 9.8.3. Proto Oncogene Drug Product Details 9.8.4. GlaxoSmithKline Proto Oncogene Production, Revenue and Gross Margin 9.9. EXELIXIS 9.9.1. Business Overview 9.9.2. Company Basic Information 9.9.3. Proto Oncogene Drug Product Details 9.9.4. Exelixis Proto Oncogene Production, Revenue and Gross Margin 9.10. NOVARTIS 9.10.1. Business Overview 9.10.2. Company Basic Information 9.10.3. Proto Oncogene Drug Product Details 9.10.4. Novartis Proto Oncogene Production, Revenue and Gross Margin CHAPTER 10. PROTO ONCOGENE DRUG MARKET VALUE CHAIN ANALYSIS 10.1. PROTO ONCOGENE DRUG INDUSTRIAL CHAIN ANALYSIS 10.2. PROTO ONCOGENE DRUG KEY RAW MATERIALS ANALYSIS 10.2.1. Key Raw Materials 10.2.2. Price Trend of Key Raw Materials 10.2.3. Key Suppliers of Raw Materials 10.3. MARKETING CHANNEL 10.3.1. Direct Marketing 10.3.2. Indirect Marketing 10.3.3. Distributors/Traders 10.4. CONSUMER ANALYSIS 10.4.1. Consumer 1 10.4.2. Consumer 2 10.4.3. Consumer 3 10.4.4. Consumer 4

• ARIAD Pharmaceuticals
• AstraZeneca
• Bayer Healthcare
• Bristol-Myers Squibb
• ChemGenex Pharmaceuticals
• Dexa Medica
• Eisai Pharmaceuticals
• Exelixis
• GlaxoSmithKline
• Novartis
• Onyx Pharmaceuticals
• Pfizer
• Plexxikon

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS